MODERNA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 103.8 USD | -4.66% |
|
+2.22% | +4.84% |
| Apr. 24 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
| Apr. 24 | Moderna to Collaborate With OpenAI to Launch New Generation of Medicines | MT |
Presenter SpeechNoubar Afeyan (Executives)Good morning. I'm Noubar Afeyan, Chairman of the Boa...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
108.8
USD
Average target price
134.3
USD
Spread / Average Target
+23.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.84% | 41.68B | |
| +0.93% | 43.84B | |
| +45.26% | 41.25B | |
| -10.92% | 27.04B | |
| +7.30% | 25.53B | |
| -25.62% | 18.18B | |
| -4.03% | 12.29B | |
| +25.47% | 12.29B | |
| +6.79% | 11.15B | |
| -19.34% | 9.98B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Transcript : Moderna, Inc. - Shareholder/Analyst Call
